VelosBio CEO: Series A Success Shows Investors Back His ADC Formula

 
• By Sten Stovall

VelosBio's well-backed Series A funding round showed that investors believe his team has identified the right combination of cancer target, linker and payload for creating a successful novel ADC, the biotech's CEO told Scrip.

R&D
Investors Have Told VelosBio Not To Reveal Its ADC R&D Target Yet • Source: Shutterstock

More from Financing

More from Business